Genomic insights into the ESBL and MCR-1-producing ST648 Escherichiacoli with multi-drug resistance

Polymyxin acts as an ultimate line of refuge against the severe infections by multidrug-resistant Gram-negative pathogens. This conventional idea is challenged dramatically by the recent discovery of mobile colistin resistance gene (mcr-1) is prevalent in food animals and human beings worldwide. More importantly, the mcr-1 gene was found to be co-localized with other antibiotic resistance genes, raising the possibility that super-bugs with pan-drug resistance are emerging. However, little is reported on the genomes of the mcr-1-positive bacterial host reservoirs. Here we report genome sequencing of three human isolates of the mcr-1-positive Escherichia coli (E15004, E15015 and E15017) and define general features through analyses of bacterial comparative genomics. Further genomic mining together with sequence typing allowed us to elucidate that the MCR-1-carrying E. coli E15017 belongs to the sequence type ST648 and coproduces extended-spectrum β-lactamase (ESBL). Given the fact that ST648 has been known to associate with either New Delhi metallo-β-lactamase 1 or ESBL, our results highlighted the possibility of ST648 as an epidemic clone with multidrug resistances. Electronic supplementary material The online version of this article (doi:10.1007/s11434-016-1086-y) contains supplementary material, which is available to authorized users.

fact that ST648 has been known to associate with either New Delhi metallo-b-lactamase 1 or ESBL, our results highlighted the possibility of ST648 as an epidemic clone with multidrug resistances.
Keywords MCR-1 Á Extended-spectrum beta-lactam (ESBL) Á Colistin resistance Á ST648 The identification of the mobilized colistin resistance gene mcr-1 recently attracted extensive attention from the scientific community. MCR-1 confers resistance to polymyxins, a group of polypeptide antibiotics that are currently considered the last refuge of therapeutics against lethal challenges by Gram-negative pathogens with multidrug resistance [1,2]. Very recently, two separate groups reported the co-occurrence of MCR-1 and extended-spectrum b-lactamase (ESBL) on plasmids in Enterobacteriaceae [3][4][5][6]. However, genomic hallmarks of the bacterial host reservoir for the mcr-1-harbouring plasmids remain unclear. Here we report on their genomic compositions.
After three mcr-1-positive E. coli isolates (E15004, E15015 and E15017) were successfully screened from the microbiota of clinical diarrhea patients [7], we applied next-generation Illumina MiSeq sequencing to decode their genomic sequences. The pool of paired-end reads produced here were assembled with GS De Novo Assembler into a collection of contigs. Then the individual contigs were ordered into draft genomes with the prototypical strain of E. coli MG1655 as the reference (Fig. 1, S1) E15015, and 4,780,540 bp for strain E15017) ( Table S1). The values of their GC percentages are all approximately 50 % (Table S1), although the draft genomes identified several regions with a strong GC skew, indicative of novel insertions of genomic material.
Further comparative genomics suggests that genetic heterogeneity is present in the three mcr-1-positive E. coli isolates (Fig. 1, S2). We retrieved the sequences of seven house-keeping genes (adk, fumC, gyrB, icd, mdh, purA and recA) from the above three sequenced genomes and subjected them to analyses of Multi-Locus Sequence Typing (MLST) (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli). Unlike the epidemic spreading clone, E. coli ST131 that carried the mcr-1 gene in Denmark [8], the three mcr-1-harbouring clinical strains belong to different sequence types (i.e., E15004 is in ST40, E15015 is in ST642, and E15017 is in ST648) ( Table 1, Fig. S3), which is generally consistent with our findings from comparative genomics (Fig. 1, S2). The fact that mcr-1-harbouring E. coli isolates are classified into different sequence types argues that the dissemination of mcr-1 colistin resistance gene is ongoing by clonal expansion [9]. Given the fact that E. coli ST648 was associated with ESBL [10,11] and two variants of New Delhi metallo-b-lactamase 1 (NDM-1), NDM-5 [12] and NDM-7 [13]), we thereby were interested in determining whether or not the genes of ESBL and NDM would also be found with the mcr-1 gene in the ST648 strain, E15017.
Using ResFinder2.1, a newly-improved database for identifying antibiotic resistance genes (https://cge.cbs.dtu. dk/services/ResFinder), we screened the above three genomic sequences, as well as the remaining unordered contigs, which likely encode additional plasmids, for the presence of antibiotic resistance genes esp. ESBL and NDM-1 (and/or its variants). As anticipated, a 100 % identical mcr-1 gene was observed in the unordered contigs in each of the three strains. NDM-1 variants were not found, which we then verified by PCR-based detection (not shown). Unexpectedly, no other antibiotic resistance gene besides mcr-1 is found in the strain E15004 (ST40) (not shown), whereas multiple drug-resistance genes apart from mcr-1 were identified in the unordered contigs from the other two strains, E15015 (ST642) and E15017 (ST648) ( Table 2, S2). In particular, the blaCTX-M-15 gene that encodes ESBL was found to be present in the ST648 strain, E15017 (Table 2). Additionally, we noted that the mcr-1 and blaCTX-M-15 are located inside distinct unordered contigs, suggesting the possibility that they are encoded on different plasmids. This represents the first example of a clinical clone of E. coli with a sequence type of ST648 that has the potential to spread MCR-1 colistin resistance together with ESBL resistance.
In summary, our data provides genomic insights into three strains of mcr-1-positive E. coli with multiple drug resistance, which reveals the increasing possibility of ST648 becoming an epidemic vector for circulation/spread of the mcr-1 colistin resistance gene in China. As the inter/ intra-species dissemination of the mcr-1 gene has been linked to the spread of other drug resistance including ESBL [11] and NDM-1 variants [12,13], our findings underscore the urgent need to modulate and control the use of colistin in veterinary/clinical practices, which might facilitate prevention of the further emergence of superbugs with multi-drug resistance.